Leading science, pioneering therapies
CRM Publications

An abundant perivascular source of stem cells for bone tissue engineering.

TitleAn abundant perivascular source of stem cells for bone tissue engineering.
Publication TypeJournal Article
Year of Publication2012
AuthorsJames AW, Zara JN, Corselli M, Askarinam A, Zhou AM, Hourfar A, Nguyen A, Megerdichian S, Asatrian G, Pang S, Stoker D, Zhang X, Wu B, Ting K, Péault B, Soo C
JournalStem Cells Transl Med
Volume1
Issue9
Pagination673-84
Date Published2012 Sep
ISSN2157-6564
KeywordsAdipose Tissue, Adventitia, Animals, Antigens, CD146, Antigens, CD34, Antigens, CD45, Bone and Bones, Bone Regeneration, Cell Separation, Humans, Mesenchymal Stromal Cells, Mice, Pericytes, Tissue Engineering, Tissue Scaffolds, Wound Healing, Wounds and Injuries
Abstract

Adipose tissue is an ideal mesenchymal stem cell (MSC) source, as it is dispensable and accessible with minimal morbidity. However, the stromal vascular fraction (SVF) of adipose tissue is a heterogeneous cell population, which has disadvantages for tissue regeneration. In the present study, we prospectively purified human perivascular stem cells (PSCs) from n = 60 samples of human lipoaspirate and documented their frequency, viability, and variation with patient demographics. PSCs are a fluorescence-activated cell sorting-sorted population composed of pericytes (CD45-, CD146+, CD34-) and adventitial cells (CD45-, CD146-, CD34+), each of which we have previously reported to have properties of MSCs. Here, we found that PSCs make up, on average, 43.2% of SVF from human lipoaspirate (19.5% pericytes and 23.8% adventitial cells). These numbers were minimally changed by age, gender, or body mass index of the patient or by length of refrigerated storage time between liposuction and processing. In a previous publication, we observed that human PSCs (hPSCs) formed significantly more bone in vivo in comparison with unsorted human SVF (hSVF) in an intramuscular implantation model. We now extend this finding to a bone injury model, observing that purified hPSCs led to significantly greater healing of mouse critical-size calvarial defects than hSVF (60.9% healing as opposed to 15.4% healing at 2 weeks postoperative by microcomputed tomography analysis). These studies suggest that adipose-derived hPSCs are a new cell source for future efforts in skeletal regenerative medicine. Moreover, hPSCs are a stem cell-based therapeutic that is readily approvable by the U.S. Food and Drug Administration, with potentially increased safety, purity, identity, potency, and efficacy.

DOI10.5966/sctm.2012-0053
Alternate JournalStem Cells Transl Med
PubMed ID23197874
PubMed Central IDPMC3659737
Grant List5T32DE007296-14 / DE / NIDCR NIH HHS / United States
G1000816 / / Medical Research Council / United Kingdom
R21 DE0177711 / DE / NIDCR NIH HHS / United States